In addition, serum P-tau-181 concentrations are increased in T2DM patients, and more studies are needed to clarify the role of serum P-tau-181 as a potential biomarker of diabetic mild cognitive impairment. The gene discussed is MAPT; the disease is type 2 diabetes mellitus.